Phase one dose finding study of capecitabine (Xeloda®), radiotherapy and cisplatin in the treatment of locally advanced squamous cervical cancer

Gynecologic Oncology

Volumn 97, Issue 3, 2005, Pages 790-795

  Stokes, Zuzana ^a   Symonds, Paul ^b   Habeshaw, Tim ^c   Reed, Nick ^c   Curto, Jorge ^c   Joynson, Claire ^d   Chan, Steve ^d  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^d NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Capecitabine; Cervical carcinoma; Combined chemoradiotherapy; Phase I study

Indexed keywords

CAPECITABINE; CISPLATIN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEMATURIA; HUMAN; LEUKOPENIA; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIATION RESPONSE; SIDE EFFECT; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; URINARY FREQUENCY; UTERINE CERVIX CARCINOMA; VAGINA ATROPHY; VAGINA MUCOSA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MIDDLE AGED; RADIOTHERAPY; UTERINE CERVICAL NEOPLASMS;

EID: 20444473694     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.03.020     Document Type: Article

References (19)

1. P. Pisani, D.M. Parkin, and F. Bray Estimates of the world wide mortality from 25 cancers in 1990 Int. J. Cancer 83 1999 18 29
2. M. Morris, P.J. Eiffel, and J.D. Lu Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high risk cervical cancer N. Eng. J. Med. 340 1999 1137 1143
3. P.G. Rose, B.N. Bundy, and E.B. Watkins Concurrent cisplatin based radiotherapy and chemotherapy for locally advanced cervical cancer N. Eng. J. Med. 340 1999 1144 1153
4. C.W. Whitney, W. Sause, and B.N. Bundy Randomised comparison of Fluorouracil plus Cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIb-IVa carcinoma of cervix with negative para-aortic nodes; a Gynaecologic Oncology Group and South West Oncology Group study J. Clin. Oncol. 17 1999 1339 1348
5. H.M. Keys, B.N. Bundy, and F.B. Stehman Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky Stage Ib cervical carcinoma N. Engl. J. Med. 340 1999 1154 1161
6. P.J. Eifel, K. Winter, and M. Morris Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high risk cervical cancer: an update of Radiation Therapy Oncology Group Trial (RTOG) 90-01 J. Clin. Oncol. 22 2004 872 880
7. J.A. Green, J.M. Kirwan, and Tierney Systemic review and meta-analysis of randomised trials of concomitant chemotherapy and radiotherapy for cancer of uterine cervix: better survival and reduced distant recurrence rate Lancet 358 2001 781 786
8. H. Lukka, H. Hirte, and A. Fyles Concurrent cisplatin based chemotherapy plus radiotherapy for cervical cancer-A meta-analysis Clin. Oncol. 14 2002 203 212
9. P. Bonomi, J.A. Blessing, and E.F. Stehman Randomised trial of three Cisplatin dose schedules in squamous cell carcinoma of the cervix: a Gynaecological Oncology Group study J. Clinical Oncology 3 1985 1079 1085
10. D.P. Ryan, C.C. Compton, and R.J. Mayer Carcinoma of the anal cancer N. Eng. J. Med. 342 2000 792 800
11. A. Herskovia, K. Martz, and M. Al-Sarraf Combined chemotherapy and radiotherapy compared to radiotherapy alone in patients with cancer of the oesophagus N. Eng. J. Med. 326 1992 1592 1597
12. M. Miwa, M. Ura, and M. Nishida Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectivity in tumors by enzymes concentrated in human liver and cancer tissue Eur. J. Cancer 34 1998 1274 1281
13. J. Schuller, J. Cassidy, and T. Dumont Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Cancer Chemother. Pharmacol. 45 2000 291 297
14. M. Ueda, Y. Terai, and K. Kumaga Correlation between thymidine phosphorylase expression and invasion phenotype in cervical carcinoma cells Int. J. Cancer 91 2001 778 782
15. N. Sawada, T. Ishikawa, and F. Sekiguchi X ray irradiation induces thymidine phosphorylase and enhances the efficacy of Capecitabine (Xeloda) in human cancer Xenografts Clin. Cancer Res. 5 1999 2948 2953
16. J. Dunst, T. Reese, and T. Sutter Phase I trial evaluating the concurrent combination of radiotherapy and Capecitabine in rectal cancer J. Clin. Oncol. 20 2002 3983 3991
17. C. Rodel, G. Grabenbauer, T. Papadopoulos, W. Hohenberger, H.-J. Schmoll, and R. Sauer Phase 1/2 trial of capecitabine oxaliplatin and radiation for rectal cancer J. Clin. Oncol. 21 2003 3098 3104
18. R. Glynn-Jones, D. Sebag-Montefiore, and A. McDonald A phase 1 study of preoperative radiation and capecitabine in combination with oxaliplatin in locally advanced rectal cancer Proc. ASCO 22 2003 1174
19. L. Torecillas, G. Ballesteros, and P. Cervantes Capecitabine chemoradiation for stage IIb-IIIb cervical cancer Preliminary Phase I Results Mexican Oncology Group Proc ECCO vol. 12 2003 163